P/B
5,7
Quantum Cyber
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
$115.2M
Market Cap • 9/25/2026
2021
(5 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
308,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,8
EPS
—
Market Cap
Market Cap
115,2M
EV
102M
EV/Revenue
273,6
EV/EBITDA
-4,3
EV/EBIT
-4,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-19,1%
Total Yield
-19,1%
Payout
0%
Retained Earnings
-121M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
2507,1%
Capex/Revenue
36,9%
Capex/D&A
40%
Capex/OCF
-1%
SBC/OCF
—
% PPE
0,6%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
5,6
Quick Ratio
4,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!